创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

BIAN Zhengying, XU Zhuo, TANG Tiejun, GUO Wei. Advances of Research on Therapies for Inducing Tumor Immunogenic Cell Death[J]. Progress in Pharmaceutical Sciences, 2021, 45(2): 119-129.
Citation: BIAN Zhengying, XU Zhuo, TANG Tiejun, GUO Wei. Advances of Research on Therapies for Inducing Tumor Immunogenic Cell Death[J]. Progress in Pharmaceutical Sciences, 2021, 45(2): 119-129.

Advances of Research on Therapies for Inducing Tumor Immunogenic Cell Death

  • It is fundamental to activate systemic immune response for long-term anti-tumor efficacy in vivo. Radiotherapy and chemotherapy can not only induce apoptosis, but also immunogenic cell death (ICD) of tumor cells. Once tumor cells undergo ICD, dying cells release damage-related molecular patterns (DAMPs), which then recruit antigen-presenting cells to engulf and process tumor cell antigens, and further activate adaptive immune response. Therefore, the application of ICD inducers in tumor therapy is of great significance for improving the prognosis and prolonging survival of cancer patients. This article reviews the biomarkers of ICD and the research progress of ICD inducers to provide reference for the clinical application of ICD inducers.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return